Thyroid function in patients with type 1 diabetes mellitus and chronic kidney disease receiving renal replacement therapy
Keywords:type 1 diabetes mellitus, thyroid gland, renal replacement therapy, chronic kidney disease
Background. Impaired thyroid function is a common endocrine pathology among patients with chronic kidney disease (CKD), including those receiving renal replacement therapy. The results of the Third National Health and Nutrition Examination Survey demonstrated that the proportion of patients with hypothyroidism rises to 23 % in progressive impaired renal function. The purpose was to study the effect of renal replacement therapy on the thyroid function in patients with type 1 diabetes mellitus and CKD. Materials and methods. We assessed thyroid function in 155 diabetic patients with end-stage CKD in a cross-sectional study. When assessing the functional status of the thyroid gland, the calculated indicators were used: the peripheral conversion index and the integral thyroid index. Peripheral conversion index was calculated as the ratio of free T4 to free T3. Results. No significant differences were found between the groups of patients receiving renal replacement therapy and patients with type 1 diabetes mellitus with and without comorbid CKD in terms of total T4 and T3, thyroglobulin, thyroglobulin antibodies and thyroid peroxidase antibodies. Significantly lower rates of free T4 and free T3 were noted with a maximum decrease when receiving renal replacement therapy. A significant decrease in the levels of thyroid-stimulating hormone receptor antibodies confirms the absence of influence of autoimmunity on the origin of thyroid disorders in patients with CKD receiving renal replacement therapy. No relationship was found between the thyroid hormones and HbA1c in type 1 diabetes mellitus patients receiving renal replacement therapy, as well as between the duration of CKD and renal replacement therapy and thyroid profile. Conclusions. These changes predetermine the need to assess serum levels of free fractions of peripheral thyroid hormones, as well as hormonal studies immediately after the hemodialysis procedure.
Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005;67(3):1047–1052. doi:10.1111/j.1523-1755.2005.00169.x.
Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1296–1300. doi:10.2215/CJN.00800208.
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499. doi:10.1210/jcem.87.2.8182.
Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004;19(5):1190–1197. doi:10.1093/ndt/gfh096.
Rhee CM, Brent GA, Kovesdy CP, et al. Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015;30(5):724–737. doi:10.1093/ndt/gfu024.
Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–1049. doi:10.1161/CIRCULATIONAHA.112.096024.
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270–278. doi:10.7326/0003-4819-132-4-200002150-00004.
US Renal Data System. USRDS 2014 Annual Data Report: Volume 2 – End-Stage Renal Disease (ESRD) in the United States. Bethesda, MD; US Renal Data System; 2014. Available from: https://www.usrds.org/2014/view/.
You AS, Sim JJ, Kovesdy CP, et al. Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrol Dial Transplant. 2019;34(12):2095–2104. doi:10.1093/ndt/gfy289.
Shin DH, Lee MJ, Kim SJ, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2012;97(8):2732–2740. doi:10.1210/jc.2012-1663.
Liu P, Liu R, Chen X, et al. Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study. Curr Med Res Opin. 2015;31(12):2233–2240. doi:10.1185/03007995.2015.1094044.
Kandor VI, ed. Synthesis, secretion and metabolism of thyroid hormones: Clinical endocrinology. SPb, Russian Federation: Piter; 2002. 122-127 pp. (in Russian).
Rebrova O. Statistical analysis of medical data. Application software package Statistica. Moskow: Media Sphere; 2002. 312 p. (in Russian).
Authors/Task Force Members:, Catapano AL, Graham I, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344. doi:10.1016/j.atherosclerosis.2016.08.018.
Carrero JJ, Stenvinkel P, Lindholm B, authors. Endocrine Aspects of Chronic Kidney Disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Brenner BM, eds. Brenner and Rector's The Kidney E-Book. 9th ed. Philadelphia: Elsevier Saunders; 2011. 21224-2137 pp.
Wiersinga WM, van den Berghe G, authors. Nonthyroidal Illness Syndrome. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s The Thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. 912 p.
Pankiv VI, Yuzvenko TYu, Pankiv IV. Type 2 diabetes mellitus and subclinical hypothyroidism: focusing on the role of cholecalciferol. Problems of endocrine pathology. 2019;2:46-51. doi:10.21856/j-PEP.2019.2.07.
How to Cite
Copyright (c) 2020 A.G. Sazonоva, T.V. Mokhort, N.V. Karlovich, V.S. Snapkov, O.E. Valovik, O.V. Ilinchik
This work is licensed under a Creative Commons Attribution 4.0 International License.